Literature DB >> 16261628

Second hit deletion size in von Hippel-Lindau disease.

Sven Gläsker1, Tae-Sung Sohn, Hiroaki Okamoto, Jie Li, Russell R Lonser, Edward H Oldfield, Alexander O Vortmeyer, Zhengping Zhuang.   

Abstract

von Hippel-Lindau (VHL) disease is caused by germline mutations of the VHL tumor suppressor gene. Affected individuals are predisposed to development of multiple neoplastic and preneoplastic lesions of different organs. A "second hit," which is usually represented by deletion in the wild-type VHL allele at 3p25, is necessary for initiation of tumor formation. The impact of the size of this deletion is thought to be critical, because other tumor suppressor genes are located nearby, but this has not yet been studied in detail. We mapped the deletion size of the "second hit" in microdissected tissue from 16 different VHL-associated lesions from the same patient using 10 polymorphic chromosome 3 markers. We found that the deletion size is highly variable, ranging from short deletions around the VHL gene to complete loss of the chromosome 3. The deletion sizes are not correlated with the site of the germline mutation, the affected organ, or the type or biological behavior of the tumor. Even preneoplastic cystic structures may harbor entire loss of the chromosome 3, suggesting that loss of VHL gene function alone is not immediately causative for neoplastic growth, but further events, either mutations and deletions in other chromosomes or epigenetic or other than genetic phenomena, are required for tumor formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16261628     DOI: 10.1002/ana.20704

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  Neurological surgery at the National Institutes of Health.

Authors:  Gautam U Mehta; John D Heiss; John K Park; Ashok R Asthagiri; Kareem A Zaghloul; Russell R Lonser
Journal:  World Neurosurg       Date:  2010-07       Impact factor: 2.104

2.  Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.

Authors:  Ying Wang; Jingyun Yang; Guhong Du; Dexuan Ma; Liangfu Zhou
Journal:  Mol Carcinog       Date:  2017-06-30       Impact factor: 4.784

3.  Risk of new tumors in von Hippel-Lindau patients depends on age and genotype.

Authors:  Marie Louise Mølgaard Binderup; Esben Budtz-Jørgensen; Marie Luise Bisgaard
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

4.  Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.

Authors:  Christian A Koch; Frederieke M Brouwers; Alexander O Vortmeyer; Andrea Tannapfel; Steven K Libutti; Zhengping Zhuang; Karel Pacak; Hartmut P H Neumann; Ralf Paschke
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

5.  Pathology of the Nervous System in Von Hippel-Lindau Disease.

Authors:  Alexander O Vortmeyer; Ahmed K Alomari
Journal:  J Kidney Cancer VHL       Date:  2015-06-11

6.  The incidence of consecutive manifestations in Von Hippel-Lindau disease.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Roeliene C Kruizinga; Rachel S van Leeuwaarde; Rachel Giles; Maran J W Olderode-Berends; Thera P Links
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

Review 7.  The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.

Authors:  Petra Hudler; Mojca Urbancic
Journal:  Genes (Basel)       Date:  2022-02-17       Impact factor: 4.096

8.  Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors.

Authors:  Zhengping Zhuang; Jason M Frerich; Kristin Huntoon; Chunzhang Yang; Marsha J Merrill; Ziedulla Abdullaev; Svetlana D Pack; Sharon B Shively; Gordon Stamp; Russell R Lonser
Journal:  Sci Rep       Date:  2014-02-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.